Special edition – Article 3

The angiotensin receptor blocker (ARB) hypertensive market – timeline to generics

In our final article on generic medicines we consider where the angiotensin II receptor blockers (ARBs) can play a useful role in managing hypertension and focus on the developments in the ARB market – notably the impending loss of patent protection for many ARBs. Dr Peter Budden, GP and prescribing advisor in Salford, helps explore the potential implications of the upcoming ARB patent expiries on prescribing and drugs savings.

Download the PDF of Article 3 here